Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Vignette Bio in the transaction. Vignette Bio (“Vignette”) and EpimAb Biotherapeutics, Inc. (“EpimAB”) announced they have entered into...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented JenaValve Technology in the transaction. Involved fees earner: Heather Aune – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented BillionToOne in the transaction. BillionToOne, a next-generation molecular diagnostics company, announced it has raised $130 million in Series...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Colossal Biosciences on the deal. Colossal Biosciences, a genetic engineering company, announced its $150 million Series B financing led by United States Innovative Technology...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented BillionToOn on the deal. BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to...
You must be a Standard 1 Year member to access this content.
